Soleno Therapeutics Inc (NASDAQ:SLNO) major shareholder Jack W. Schuler acquired 6,000 shares of the business’s stock in a transaction on Sunday, April 12th. The stock was acquired at an average cost of $2.08 per share, with a total value of $12,480.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of NASDAQ:SLNO opened at $1.84 on Monday. The firm has a 50 day moving average of $2.99 and a 200-day moving average of $2.80. The stock has a market capitalization of $82.27 million, a PE ratio of -2.39 and a beta of 0.57. Soleno Therapeutics Inc has a 12 month low of $1.18 and a 12 month high of $4.39.
Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.07. On average, sell-side analysts forecast that Soleno Therapeutics Inc will post -0.59 EPS for the current fiscal year.
Several large investors have recently modified their holdings of SLNO. AE Wealth Management LLC acquired a new position in Soleno Therapeutics during the 1st quarter worth approximately $25,000. BlackRock Inc. increased its position in Soleno Therapeutics by 25.2% during the 1st quarter. BlackRock Inc. now owns 85,745 shares of the company’s stock worth $205,000 after purchasing an additional 17,281 shares in the last quarter. Geode Capital Management LLC increased its position in Soleno Therapeutics by 62.1% during the 4th quarter. Geode Capital Management LLC now owns 56,899 shares of the company’s stock worth $167,000 after purchasing an additional 21,802 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Soleno Therapeutics during the 1st quarter worth approximately $98,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. acquired a new position in Soleno Therapeutics during the 4th quarter worth approximately $134,000. Institutional investors own 46.44% of the company’s stock.
About Soleno Therapeutics
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Read More: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.